Who actually writes the prescription in your clinic?

The two questions nobody separates

Almost every confusion in this area comes from collapsing two different acts into one word, “ordering.”

Procurement is how medication gets into your building or to your patient’s door. It is a purchasing act, governed by pharmacy law and by which model you are buying from.

The clinical decision is whether this particular person should receive this particular medication today. It is a practice-of-medicine act, governed by your state’s rules on evaluation, delegation, and supervision.

Compliant procurement never satisfies the clinical decision, and a good clinical decision never substitutes for compliant procurement. A clinic can hold perfectly legitimate 503B office stock and still be non-compliant in how it administers it — and in the cases we see that is one of the most common structural gaps.

What each sourcing model asks of the prescriber

Under either model the preparations are compounded, not manufactured: compounded medications are not FDA-approved, and the FDA does not review compounded medications for safety or efficacy.

503A — patient-specific

A 503A pharmacy compounds against a prescription for a named, identified patient. So the prescriber has to exist before the medication does: someone with prescriptive authority in the patient’s state evaluates that patient, decides on the therapy, and writes for them. The pharmacy fills that prescription and ships to the patient or, where permitted, to the practice for that patient.

Practical consequences owners underestimate: as a general rule the prescriber must be authorised to practise where the patient is, not merely where the clinic is, which is what makes multi-state telehealth programs a licensing exercise before they are a marketing exercise. A few states offer an out-of-state telehealth registration route rather than full licensure, so check the map state by state rather than assuming. Refills, dose changes, and discontinuations are all prescribing decisions too, so the relationship has to be ongoing rather than a signature at intake.

503B — office stock

A 503B outsourcing facility may supply without a patient-specific prescription, so the practice can hold stock. That is the appeal: same-day treatment, no wait for a fill. But the prescriber does not disappear from the picture — the act simply moves. Procurement happens on the facility’s medication order; administration to a specific patient still requires a practitioner’s order for that person, after an evaluation.

So 503B changes when the prescriber is needed, not whether. Clinics that read office stock as “we can treat without a prescriber” have misread the most consequential sentence in the model.

Prescriber and medical director are not synonyms

They are often the same human, which is exactly why the distinction gets lost until it matters.

The prescriber makes an individual clinical decision for an individual patient and takes responsibility for it. The compounding pharmacy account keys to this person’s license.

The medical director holds ongoing clinical oversight for the practice: protocols, what may be delegated to whom, quality, adverse-event handling, and in many states the supervisory or collaborative relationship a nurse practitioner or physician assistant practices under.

You can have a prescriber and no meaningful medical direction — a signature that writes when asked and reviews nothing. It works right up until someone asks who approved the protocol, who reviewed the charts, and who was responsible when a patient had a reaction. Our guide to medical director coverage in all 50 states covers the structures and the ownership language worth insisting on.

Who is allowed to be the prescriber

Physicians, and depending on the state, nurse practitioners and physician assistants. What varies is how much independence the NP or PA has, and that variation is the single biggest driver of what your staffing and cost structure look like. These are the American Association of Nurse Practitioners classifications.

• Full practice authority — the NP may evaluate, diagnose and prescribe under the exclusive authority of the state board of nursing.
• Reduced — a career-long collaborative agreement or similar arrangement with a physician is required for at least one element of practice.
• Restricted — career-long supervision, delegation or team management by a physician is required.

For an owner this is a cost line as much as a legal one: in reduced and restricted states the collaborating or supervising physician is a recurring expense and a single point of failure the day that relationship ends. Physician assistant frameworks vary on a separate axis again. Your state’s current classification, the PA framework, and who may perform cosmetic injections are all on the state compliance map, each with the source it was checked against.

Standing orders, protocols, and the exam

Where a state permits them, a standing order or protocol lets defined personnel perform defined tasks for patients meeting stated criteria. They are an organising tool for delegation, and they are genuinely useful.

What they are not is a replacement for evaluating the patient. The evaluation that establishes the treatment plan — often called a good-faith examination — answers a different question: should this person be treated at all, today, with this. A standing order answers who may carry it out once that decision exists.

Treating the two as interchangeable is among the most commonly cited deficiencies in med spa enforcement actions, and it is an easy mistake to make because a well-run protocol feels like it covers the decision. Whether telehealth satisfies the exam, and who may perform it, is the detail that varies most between states.

What breaks when the prescriber is missing

Four failures, in roughly the order clinics hit them:

• The pharmacy account will not activate. Diligence is done, terms agreed, and then nothing happens, because there is no prescriber of record to open it under.
• Office stock sits unusable. The medication is in the building and compliantly procured, and there is no one to make the clinical decision for the patient in front of you.
• Staff get asked to work above their license. This is the quiet one. Under revenue pressure, a nurse ends up making a call that is not theirs to make, and neither they nor the owner intended it.
• The relationship ends abruptly. A collaborating physician resigns in a reduced or restricted state, and the practice discovers its NP cannot prescribe on Monday.

The sequence that works

Prescriber, then pharmacy, then platform, then patients. In that order, because each step is a precondition for the next: the pharmacy account opens under the prescriber, the platform routes what the pharmacy fills, and marketing to patients before the first three are in place creates demand you have no compliant way to fill.

Most launch problems we see are this sequence run backwards — patients first, because that is the exciting part. The same ordering logic applied to a weight-management launch specifically is in adding GLP-1 in the right order; the two sourcing models are compared in 503A vs 503B in plain English, the pharmacy half is in how to vet a compounding pharmacy and pharmacy access; and the coverage itself is the doctor’s network, which is one relationship across all 50 states rather than a contract per state.

The questions worth answering before you order anything

• Who is the prescriber of record, and are they licensed in every state my patients are in?
• Is that person also the medical director — and if not, who is, and what do they actually review?
• In my state, may my NP or PA prescribe independently, or is a collaborative or supervisory agreement required?
• Who may perform the evaluation, and does telehealth satisfy it here?
• Who may administer, and must the supervising practitioner be physically present?
• If my collaborating physician resigned tomorrow, what stops on Monday?

The last one is the test most practices have never run.